Introduction {#Sec1}
============

Herpes simplex virus (HSV) is the cause of acute viral encephalitis in 50--70% of cases where a virus can be identified \[[@CR1]\]. Both HSV-1 and HSV-2 can cause encephalitis (HSE), which is predominantly located in the temporal lobes and the limbic system. From a histopathological viewpoint, HSE is a necrotizing process with perivascular inflammation and edema. Clinical care guidelines since the 1980s have emphasized increased awareness and swift initiation of treatment with acyclovir in encephalitic syndromes, lowering the mortality to below 20% \[[@CR2], [@CR3]\]. HSE, however, continues to result in substantial overall morbidity and mortality \[[@CR4], [@CR5]\]. Half of the survivors experience moderate to severe disability after 1 year \[[@CR6]\]. Their quality of life is significantly impacted by epilepsy, psychiatric disorders, cognitive problems, dementia, headache, and alcohol abuse \[[@CR5], [@CR7], [@CR8]\].

Cerebrovascular disease occurs as a complication of a variety of central nervous system (CNS) infections \[[@CR9]\]. Many patients with infectious cerebral vasculopathies require intensive care with a generally poor prognosis \[[@CR10], [@CR11]\]. A recent analysis of 4871 cases of HSE in the USA reported intracranial hemorrhage in 2.7% and ischemic stroke in 5.6% \[[@CR12]\]. However, there has been no systematic study conducted to evaluate clinical presentations, causative agents, pathogenesis, and outcome of cerebrovascular complications in HSE. Most knowledge about HSV-related cerebrovascular disease is provided by case reports. Therefore, an appraisal of the current state of understanding in this field is much needed. We systematically studied HSV-related cerebral vasculopathies reported in the literature.

Methods {#Sec2}
=======

We conducted a systematic review of medical literature to identify all published cases of cerebrovascular manifestations of HSV using MEDLINE/PubMed, Web of Science, and Google Scholar. The study period was January 2000 to July 2018. There were no language restrictions; non-English articles were included and translated using online resources such as Google Translate. Search terms used were "HSV," "herpes," "herpetic," "meningoencephalitis," or "encephalitis" and one of the following terms: "ischemia," "infarction," "stroke," "hemorrhage," "hematoma," "vasculopathy," or "vascular complication." We reviewed titles, abstracts, and full articles. References in each identified article were reviewed to identify additional cases.

The inclusion criteria were (1) radiological evidence of cerebrovascular manifestations of HSV (infarction, hemorrhage, or vasculopathy characterized by features of vasculitis, thrombosis, or aneurysm) by computed tomography (CT) or magnetic resonance imaging (MRI), (2) mandatory confirmation of HSV infection by analysis of cerebrospinal fluid according to the diagnostic criteria proposed in a recent consensus paper \[[@CR13]\], and (3) exclusion of other causes for stroke. We limited our search to publications addressing HSE in children and adults; thus, neonatal cases were excluded. Details of the evaluation and selection process are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of patient selection

We extracted the following data: demographics, time from onset of symptoms to admission, neurological symptoms at presentation (classification: encephalitis, meningitis, stroke, other), and presence of imaging surrogates of cerebrovascular disease on admission and during the acute course. Stroke was defined according to the World Health Organization as "rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 h or longer or leading to death, with no apparent cause other than of vascular origin." Data on imaging included modality (CT or MRI), presence of encephalitis in a typical location (frontal or temporal lobe), characteristics of hemorrhage or ischemic lesion (unifocal or multifocal), distribution within vascular territories (anterior or posterior circulation or both), and features suggestive of vasculitis (small or large vessels or both). CSF data included cell count and the technique used to confirm CNS HSV infection (PCR, antibody, histology). Large vessel disease refers to involvement of the internal carotid artery (ICA), the vertebral artery (VA), the anterior cerebral artery (ACA) and its main branches, the middle cerebral artery (MCA) and its main branches, the posterior cerebral artery (PCA), and the basilar artery (BA) and its main branches \[[@CR14]\]. Small vessels included the small penetrating arteries (e.g., the lenticulostriate arteries) that supply the deep structures of the brain. We also studied the use of steroids, as well as significant comorbidities. Outcome was classified according to the modified Rankin scale (mRS). Good outcome was defined as an mRS score of 0--2, and poor outcome as 3--5. Fatality (mRS 6) was categorized as an additional subgroup.

Statistical analysis was performed using the GraphPad Prism 7 software (La Jolla, CA).

Results {#Sec3}
=======

Systematic review {#Sec4}
-----------------

Details of the selection process are outlined in Fig. [1](#Fig1){ref-type="fig"}. We were unable to include three potentially relevant manuscripts as they were not accessible. These papers exclusively reported hemorrhagic manifestations of HSE \[[@CR15]--[@CR17]\]. We eventually analyzed a total of 36 manuscripts comprising 38 patients (Fig. [1](#Fig1){ref-type="fig"}). There were 27 cases of intracerebral hemorrhage \[[@CR18]--[@CR42]\], 10 with cerebral infarction \[[@CR43]--[@CR52]\], and 1 patient with venous sinus thrombosis \[[@CR53]\].

General and comparative analysis {#Sec5}
--------------------------------

The median age of the reported patients was 43 years (interquartile range (IQR) 27--65), and 19 (50%) were male. Six patients (15%) were younger than 18 years. There were no statistical differences of age and gender between patients with hemorrhagic and ischemic complications. Among cases where PCR distinguished between HSV-1 and HSV-2, HSV-1 was the predominant virus identified in cases with intracerebral hemorrhage (16/18, 89%). In contrast, cases with infarction were dominated by HSV-2 (5/7, 71%). There were patients with PCR-confirmed HSV CNS infection in whom the methodology did not distinguish between the two types (26% in the hemorrhage and 20% in the infarction group). Infectious comorbidities in patients with hemorrhage included HIV (*n* = 1) and hepatitis C (*n* = 1). There was a single case of systemic lupus erythematosus and immunosuppression in the infarction group. Demographics, clinical presentation, imaging, and outcome are presented separately for patients with hemorrhage and ischemia in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively.Table 1Overview of demographics, clinical, and radiological findings in patients with hemorrhagic manifestations of HSV CNS infectionDemographics *n*27 Median age (IQR), years40 (26--54) \< 18 years23% (4/27) Male sex55% (15/27) Days from symptom onset to admission (median, IQR), *n* = 243.5 (2--7)Clinical presentation Encephalitis93% (25/27) Stroke-like4% (1/27) Unspecific4% (1/27)Diagnostic testing HSV-1 (PCR of CSF)59% (16/27) HSV-2 (PCR of CSF)7% (2/27) HSV not distinguished (PCR of CSF)26% (7/27) HSV not distinguished (antibody of CSF)4% (1/27) PCR negative for HSV (CSF)4% (1/27)CSF findings Pleocytosis (\> 4 cells/μl)88% (21/24) Median cell count^\#^(cells/μl, IQR, *n* = 23)88 (25--387)Neuroimaging Hemorrhage on first imaging32% (8/25) Hemorrhage after admission68% (17/25) Days from admission to detection of hemorrhage (median, IQR)10 (9--14) Hemorrhage within HSE predilection sites89% (24/27) Bilateral temporal lobe HSE33% (8/24) Atypical localization of hemorrhage7% (2/27) No encephalitic lesion4% (1/27) Evidence for vasculitis0% (0/9)Intervention Hematoma evacuation30% (8/27)Outcome Good outcome (mRS 0--2)38% (8/24) Unfavorable outcome (mRS 3--5)41% (11/24) Fatality21% (5/24)^\#^In patients with pleocytosis. *IQR* interquarile rangeTable 2Overview of demographics, clinical, and radiological findings in patients with ischemic manifestations of HSV CNS infectionDemographics *n*10 Median age (IQR), years47 (26--69) \< 18 years20% (2/10) Male gender30% (3/10) Days from symptom onset to admission*n* = 3 on day 1, *n* = 1 on day 2Clinical presentation Encephalitis50% (5/10) Stroke-like30% (3/10) Meningitis20% (2/10)Diagnostic testing HSV-1 (PCR of CSF)20% (2/10) HSV-2 (PCR of CSF)50% (5/10) HSV not distinguished (PCR of CSF)20% (2/10) PCR negative for HSV-1 (CSF) but antibody rise10% (1/10)CSF findings Pleocytosis (\> 4 cells/μl)100% (10/10) Median cell count^\#^ (cells/μl, IQR, *n* = 10)42 (15--199)Neuroimaging Ischemia on first brain imaging50% (5/10) Hemorrhage on first imaging, ischemia later20% (2/10) Presence of loco-typico HSV lesion10% (1/10) Evidence for vasculitis63% (5/8) Affected vessels  Small-sized0%  Large-sized100% (5/5) Affected areas of circulation  Anterior30% (3/10)  Posterior20% (2/10)  Anterior and posterior50% (5/10) Distribution of lesions  Single10% (1/10)  Multiple90% (9/10)Intervention Steroid treatment40% (4/10)Outcome Good outcome (mRS 0--2)56% (5/9) Unfavorable outcome (mRS 3--5)44% (4/9) Fatality0%^\#^In patients with pleocytosis. *IQR* interquartile range, *PCR* polymerase chain reaction, *CSF* cerebrospinal fluid, *HSV* herpes simplex virus

Intracerebral hemorrhage {#Sec6}
------------------------

The clinical syndrome preceding admission was almost exclusively of encephalitis (93%). We found a median time lag of 3.5 days from symptom onset to hospital admission. The hematoma developed as a complication of HSV encephalitis in a typical location in most of the patients (89%). The parietal and occipital lobe, as well as deep brain structures, were the remaining locations of hematoma. The majority of bleedings were classified as parenchymal hemorrhage (*n* = 26), and only one case was petechial. Ventricular and/or subarachnoid blood was present in four patients. Many patients had cerebral edema, occasionally complicated by subsequent midline shift (*n* = 2), herniation (*n* = 4), or brainstem compression (*n* = 2). There was no evidence of a vasculitic pathology in the nine patients with vascular imaging and the three with histological examination of brain biopsy. No aneurysms were seen. Brain hemorrhage was detected on the first neuroimaging in eight patients (32%). More frequent was the development of hemorrhage after admission and the initiation of antiviral therapy (68%), with a time lag of a median of 10 days. Hematoma evacuation was performed in 30%. Outcome was unfavorable in 62%. The course of individual patients is presented in Table [3](#Tab3){ref-type="table"}.Table 3Characteristics of patients with hemorrhagic manifestations of HSV CNS infectionNo. (year), referenceAge, sexHSV type, diagnostic test, CSF cells countInitial clinical presentation, other findingsLocalization of encephalitisLocalization of bleeding, other characteristicsTime from symptom onset to admission, time from admission to detection of hemorrhagePresence of vasculitis (affected vessel), treatmentOutcome (mRS)1 (2001), Plantinga E \[[@CR18]\]36, mHSV-1, PCR, 33 cells/μlEncephalitis (fever, consciousness, disorientation)Left temporal, frontal, and insular areasLeft temporoparietal, hematoma, edema, midline shiftDay 6, day 10n.e., dexamethasoneMild aphasia and short-term memory disturbances (3)2 (2001), Lee JW \[[@CR19]\]15, mHSV\*, PCR, 15 cells/μlEncephalitis (fever, aphasia, confusion)Both temporal and frontal lobesLeft temporal and frontal lobe, petechial hemorrhageDay 4, on first imagingn.e.Weakness upper extremity (2)3 (2001), Lee JW \[[@CR19]\]6, mHSV\*, PCR, 5 cells/μlEncephalitis\
(fever, vomiting, altered consciousness)Left medial temporal lobeLeft temporal and frontal lobe, hematomaDay 17, on first imagingn.e.Severe bulbar dysfunction (4--5)4 (2002), Erdem G \[[@CR20]\]1, fHSV\*, PCR, 33 cells/μlEncephalitis (seizures, lethargy, fever)Both temporal, frontal, and parietal lobesRight temporal lobe, hematoma, edemaDay 6, on first imagingNoQuadriparesis (4--5)5 (2004), Biswas A \[[@CR21]\]38, mHSV-1, PCR, 0 cells/μlEncephalitis (headache, disturbed sleep)Right inferior frontal and medial temporal regionRight frontal and temporal lobe, hematoma, edemaNot specified, not specifiedNoComplete recovery (0)6 (2005), Kabakus N \[[@CR22]\]3, mHSV\*, antibody, 450 cells/μlEncephalitis (fever, headache hemiparesis)Right temporal lobeLeft parietal lobe, hematoma, edemaDay 10, on first imagingn.e.Hemiparesis (3)7 (2005), Jabbour PM \[[@CR23]\]27, mHSV-1, PCR, 189 cells/μlEncephalitis (fever, seizure)Right mesial temporal lobeRight temporal lobe, hematoma, uncal herniation, and ventricular bloodDay 2, day 9n.e., craniotomy and evacuation of hematomaNo focal neurological signs (0)8 (2006), Argyriou AA \[[@CR24]\]22, mHSV-1, PCR, 425 cells/μlEncephalitis (seizure, fever, altered consciousness)Left termporal lobeLeft parietal lobe, hematomaDay 3, day 11n.e.Complete recovery (0)9 (2007), Shelley BP \[[@CR25]\]26, mHSV\*, PCR, 130 cells/μlEncephalitis (fever, confusion, seizure)Bilateral medial temporal lobe (left \> right)Left temporal lobe, hematomaDay 1, day 18noComplete recovery (0)10 (2008), Gkrania-Klotsas E \[[@CR26]\]46, mHSV-1, PCR, 0 cells/μlEncephalitis (headache, fever, depersonalization)No lesionLeft parietal lobe, hematomaDay 7, on first imagingn.e.Returned to premorbid mental condition (0--1)11 (2009), Li JZ \[[@CR27]\]56, mHSV-1, PCR, 30 cells/μlencephalitis (fever, seizure), HIV positiveLeft medial temporal lobeLeft temporal lobe and basal ganglia, hematoma, edema, herniationDay 1, day 6 (no hemorrhage on CT on day 1)n.e., craniotomy and evacuation of hematomaMild neuropsychological deficits (2)12 (2010), Tonomura Y \[[@CR28]\]30, fHSV-1, PCR, 321 cells/μlEncephalitis (headache, fever, neuropsychological deficits, altered mental state)Bilateral (left \> right) medial temporal and frontal lobesLeft amygdaloid body, hematoma, subarachnoid, and ventricular bloodDay 2, day 5n.e.GCS 14, responds to simple orders (5)13 (2011), Takeuchi S \[[@CR29]\]54, mHSV-1, PCR, 86 cells/μlEncephalitis (fever, walking difficulty, confusion, seizure)Right temporal lobeTemporal lobe, hematomaDay 2, day 10n.e.Hemiparesis, memory disturbances (3)14 (2013), Battaglia F \[[@CR30]\]38, fHSV-1, PCR, pleocytosisEncephalitis (headache, fever, hallucinations, speech disturbances)Diffuse cerebral edema on CTLeft temporal lobe, hematoma, edema with brainstem compressionDay 3, day 9n.e., craniotomy and evacuation of hematomaDied 20 days from symptom onset (6)15 (2013), Rodriguez-Sainz A \[[@CR31]\]45, fHSV-1, PCR, 383 cells/μlEncephalitis (headache, fever, incoherent speech), hepatitis C infectionLeft medial temporal lobeLeft temporal lobe, hematoma, edema, brainstem compressionDay 2, day 9 (no lesion and no hemorrhage on CT on day 1)n.e., craniotomy and evacuation of hematomaResidual aphasia and right-sided hemiparesis (3--4)16 (2013), Rodriguez-Sainz A \[[@CR31]\]53, fHSV-1, PCR, 516 cells/μlEncephalitis (fever, memory problems, headache)Bilateral temporal lobes and insulaLeft temporal lobe, hematoma, blood in subarachnoid space and midline shiftDay 6, day 8n.e.Mild neuropsychological deficits (3)17 (2014), Yu W \[[@CR32]\]64, fHSV\*, PCR and brain biopsy, not reportedEncephalitis (headache, leg pain, seizure 5 days later)Bilateral temporal and frontal lobeRight temporal lobe, hematoma, raised intracranial pressureNo details, on first imagingNo, craniotomy and evacuation of hematomaDied on hospital day 25 (6)18 (2015), Zabroug S \[[@CR33]\]28, fHSV-1, PCR, 2/μlEncephalitis (anterograde amnesia, insomnia), 4 month postpartumRight temporal lobeSupra-tentorial bloodNo details, no detailsNoNot reported19 (2015), Bhagchandania D \[[@CR34]\]23, mHSV\*, PCR, 20/μlEncephalitis (fever, seizures, altered sensorium)Bilateral temporal and parietal lobeLeft temporal lobe, hematomaDay 4, day 15n.e.Behavioral abnormality (3--4)20 (2016), Gaye NM \[[@CR35]\]53, fHSV-2, PCR, 88 cells/μlEncephalitis (recurrent seizures, fever on day 1)Left mesial temporal lobeLeft temporal lobe, hematoma, ventricular bloodDay 2, day 18n.e.Persistent severe neuropsychological deficits (5)21 (2017), Harada Y \[[@CR36]\]71, fHSV-1, PCR, 170 cells/μlEncephalitis (fever, headache, altered mental status)Right anterior medial temporal lobe and insular cortexRight temporal lobe and right basal frontal lobe, hematoma, intraventricular bloodDay 8, day 14NoNear complete recovery (1)22 (2016), Mahale RR \[[@CR37]\]71, mHSV\*,\
PCR, 5 cells/μlEncephalitis (fever, headache, altered mental status)No loco-typico lesionsLeft parieto-occipital and right occipital region, hematomaDay 5, on first imagingn.e.Mild improvement of cortical blindness (4)23 (2016), Fisahn C \[[@CR38]\]69, fHSV\*, brain biopsy, not reportedStroke-like (acute onset of headache and right hemiparesis)No loco-typico lesionsLeft parietal lobe, hematoma, subarachnoid hemorrhageDay 1, on first imagingn.e.Died (6)24 (2017), Mueller K \[[@CR39]\]40, fHSV-2, PCR, 558 cells/μlUnspecific (headache, fever, nausea, vomiting)CT on first day normalRight temporal lobe, hemorrhage, midline shiftDay 7, day 14No, hemicraniectomy and temporal lobectomySurvived, no further details reported25 (2017), El Shimy G \[[@CR40]\]49, mPCR negative, 45 cells/μlEncephalitis (fever, headache, altered mental status)Right temporal lobe and insulaRight medial temporal lobe, hematomaDay 2, day 14NoReturned to baseline neurological status (0)26 (2013), Lo WB \[[@CR41]\]46, mHSV-1, PCR, 390 cells/μlEncephalitis (fever, headache, confusion)Left temporal lobeLeft temporal lobe, hematoma, edema, uncal herniationDay 7, day 10Craniotomy on day 6, removal of anterior temporal lobe and evacuation of hematomaGradual improvement, no further details reported27 (2018), Sivasankar C \[[@CR42]\]71, fHSV-1, IHC, n.e.Encephalitis (decreased responsiveness, hemiparesis, seizure)Both temporal and parietal lobesRight temporal lobe, hematoma, edema, uncal herniationDay 1, day 8 (postoperative)No, craniotomy for evacuation of hematoma on day 8Died on day 17 after hospital admission (6)\*PCR methodology did not distinguish between HSV-1 and HSV-2. *m* male, *f* female, *+* yes, *−* no, *n.a.* not available, *CSF* cerebrospinal fluid, *MCA* middle cerebral artery, *MP* methylprednisone, *n.e.* not evaluated, *MRI* magnetic resonance imaging, *CT* computed tomography, *HIV* human immunodeficiency virus, *IHC* immunohistochemistry

Ischemic stroke {#Sec7}
---------------

The initial clinical presentations of patients in the infarction group included encephalitis (50%), meningitis (20%), and stroke (30%). No relevant comorbidities were reported; one patient was 2 months postpartum. Forty percent of the patients were admitted within 2 days from symptom onset, but this information was missing for three patients. Initial brain imaging was performed with CT in five, with MRI in four, and using both in one case. Brain infarction was detected on the first brain imaging in 50%, and an encephalitic lesion in a typical location was present in one patient (10%). Hemorrhage preceded infarction in two patients (20%), who were assigned to the group with ischemic manifestation due to the overlap of radiological features and pathogenesis. Multiple ischemic lesions were found in 90%, located most commonly in both anterior and posterior circulations. CSF pleocytosis was abundant in all patients. Vascular imaging was performed in eight patients, with evidence for cerebral vasculitis found in 63%. This exclusively involved the large arteries. Forty percent of patients with infarction were treated with steroids. Outcome was unfavorable in 40 %, but no one died. The course of individual patients is presented in Table [4](#Tab4){ref-type="table"}.Table 4Characteristics of patients with ischemic manifestations of HSV CNS infectionNo. (year), referenceAge, sexHSV type, diagnostic test, CSF cell countClinical presentation, special featuresPresence of loco-typico HSV-encephalitisTime from symptom onset to admission, ischemia on first imagingPresence of vasculitis (affected vessel), affected brain regionSteroids, dosage (duration)Outcome (mRS)1 (2004), Alexandri NM \[[@CR43]\]31, mHSV-1, PCR, 46 cells/μlEncephalitis (fever, hallucinations, headache)YesNot reported, no (CT)No, multifocal (anterior and posterior)−Hemianopsia (2)2 (2009), Sas AM \[[@CR44]\]3, fHSV-1, PCR, 38 cells/μlEncephalitis (fever, impaired vision, nausea, vomiting)NoDay 5, yes (CT and MRI)No, multifocal (posterior)−Blindness (3)3 (2012), Zepper P \[[@CR45]\]72, mHSV-2, PCR, 588 cells/μlStroke-like (aphasia, hemiparesis)NoUnclear, no (hemorrhage on CT)Yes (various vessels), multifocal (anterior and posterior)−Moderate cognitive deficits and hemiparesis (3--4)4 (2013), Guerrero WR \[[@CR46]\]36, fHSV\*, PCR, 13 cells/μlEncephalitis (headache, diplopia with skew deviation), 2 months postpartumNoDay 2, yes (MRI)Yes (basilar artery), single lesion (posterior)MP 3 days, P 7 days, dosages not reportedInternuclear ophthalmoplegia (3)5 (2014), Terlizzi V \[[@CR47]\]10, fHSV-1, IgG antibodies appeared in CSF, 20 cells/μlStroke-like (headache and hemiparesis)NoDay 1, no (CT)Yes (distal ICA and MCA), multifocal (anterior)−Complete recovery (0)6 (2014), Snider SB \[[@CR52]\]57, fHSV-2, PCR, 1260 cells/μlMeningitis (headache, nausea, vomiting, photophobia)NoUnclear, no (hemorrhage on CT)Yes (various vessels), multifocal (anterior and posterior)Yes, dosage not reported, 21 daysMinimal deficits (1--2), resolution of stenoses7 (2016), Zis P \[[@CR48]\]45, mHSV-2, PCR, 64 cells/μlEncephalitis (fever, confusion)NoDay 1, no (CT)Not studied, multifocal (anterior)−Mild cognitive deficits (2)8 (2016), Joshi P \[[@CR49]\]48, fHSV-2, PCR, 16 cells/μlMeningitis (fever, headache, neck stiffness), later encephalitisNoDay 120, yes (MRI)Yes (various vessels), multifocal (anterior and posterior)MP and P dosage/duration not reportedRelapsing course, outcome not reported9 (2017), Tsuboguchi S \[[@CR50]\]73, fHSV\*, PCR (6000 copies/ml), 8 cells/μlStroke-like (hemiparesis)NoDay 1, yes (MRI)Not studied, multifocal (anterior and posterior)Yes, MP 500 mg, 3 daysModified Rankin scale 510 (2017), Zhang F \[[@CR51]\]68, fHSV-2, PCR, 649 cells/μlEncephalitis (headache, numbness, hallucinations), systemic lupus, and immunosuppressionNoDay 21, yes (MRI)No, multifocal (anterior)−Complete recovery (0)\*PCR methodology did not distinguish between HSV-1 and HSV-2. *m* male, *f* female, *+* yes, *−* no, *n.a.* not available, *CSF* cerebrospinal fluid, *MCA* middle cerebral artery, *MP* methylprednisone

Venous sinus thrombosis {#Sec8}
-----------------------

There was a single case of a 31-year-old man who had been suffering from fever, photophobia, and headache for 3 days. He was treated with acyclovir for suspected HSE (predominantly lymphocytic pleocytosis, HSV confirmed in CSF). Six days after admission, he developed bilateral upper limb weakness, ataxia, and bilateral headache. A brain MRI revealed features of encephalitis in the left temporal lobe and a superior sagittal sinus thrombosis. He was started on heparin and changed to warfarin for 1 year and was asymptomatic at follow-up.

Discussion {#Sec9}
==========

On the basis of this systematic review of published cases, we propose that intracerebral hemorrhage and brain infarction are two pathogenetically distinct manifestations of CNS HSV infection. Intracerebral hemorrhage almost exclusively occurred within the temporal lobe, was related to HSV-1, and caused life-threatening complications. Intracerebral hemorrhage is most likely a complication secondary to disintegration of vessels in the context of a necrotic encephalitic process. In contrast, brain infarction is associated with HSV-2, pathomechanistically related to large-vessel vasculitis leading to multifocal ischemia, but with a less detrimental prognosis. Our study also revealed that the occurrence of cerebrovascular complications of CNS HSV infection is independent of age and gender and is not associated with comorbidities or immunosuppression.

All three alphaviruses (HSV-1, HSV-2, and varicella-zoster virus (VZV)) are dormant in trigeminal and upper cervical ganglia that innervate the cerebral arteries, dural sinuses, and other brain structures \[[@CR54], [@CR55]\]. Upon reactivation, these viruses can then travel transaxonally via an immunoprivileged route to infect the brain and arteries. HSE is a necrotizing inflammatory process typically affecting the cortex and underlying white matter of the temporal lobe \[[@CR3]\]. The insula, cingulate gyrus, and posterior orbital frontal lobe are involved less frequently. Extra-temporal involvement is well described in HSE, to occur in more than half of the cases, sometimes even without any temporal abnormalities \[[@CR56]\]. CNS pathology in HSE can be attributed to a combination of cytolytic viral replication and immune-mediated mechanisms leading to axonal and glial damage \[[@CR57]\]. Histologic examination in acute HSE often shows cytotoxic and vasogenic edema as well as necrosis with petechial hemorrhages \[[@CR58], [@CR59]\]. Accordingly, limited hemorrhage is an integral part of the disease process, but in a subgroup of patients, a proper intracerebral hematoma develops. This complication is likely to result from weakening of the neurovascular unit caused by the necrotizing process via increased permeability due to cytokine, chemokine, and protease action \[[@CR60]--[@CR62]\]. Modi et al. reported a 2.7% rate of intracerebral hemorrhage in a large cohort of HSE patients, also associated with an increased mortality \[[@CR12]\]. Here, we expand the understanding of this complication by reporting a frequent association of hemorrhage with severe edema, midline shift, herniation, and brain stem compression. Indeed, Jouan et al. reported high rates of ICU admission (32%) and mechanical ventilation (17%) in patients with HSE and a two-fold increase in mortality in those requiring ICU care \[[@CR6]\]. However, the aforementioned study could not find any predictive features for brain herniation on the first neuroimaging. In our analysis, hemorrhage occurred in most patients after admission (68%) at a median of 10 days. This indicates that the processes leading to vessel disruption requires some time. Additional factors potentially increasing susceptibility for the development of a hematoma could include the vicinity of the encephalitic process to penetrating vessels, an impaired coagulation state, and the extent of the inflammatory response. A direct link between antiviral therapy and intracerebral hemorrhage cannot be ruled out as there are cases of acyclovir-induced thrombocytopenia \[[@CR63], [@CR64]\]. The presence of thrombocytopenia carried a six-fold increased risk of mortality in a cohort of encephalitis of any type \[[@CR65]\]. Thus, both monitoring of coagulation and cautious use of anticoagulants may be advisable in severe encephalitis.

From the immunological viewpoint, an innate immune response driven by monocytes and natural killer cells dominates the early phase \[[@CR66]\]. This response is followed by extravasation and parenchymal entry of T cells, particularly cytotoxic CD8+ T cells. On a molecular level, matrix metalloproteinase-9 (MMP-9), a major regulator of collagen type IV and the main component of the neurovascular matrix, has been recognized as a key factor in this process. In a mouse model of HSE, MMP-9 activity increased during the early phase with peak levels in fully developed HSE, resulting in compromise of the neurovascular unit \[[@CR67]\]. This phenomenon is also known from hemorrhagically transformed ischemic stroke in humans, where an upregulation of MMP-9 has also been linked to disruption of the neurovascular unit. \[[@CR68]\] A few studies proposed a beneficial role of adjuvant steroids in HSE, which may restrict detrimental immune responses by mechanisms such as inducing apoptosis of immune cells in peripheral blood and within the CNS, or neutralization of MMP-9 activity by raising tissue inhibitor of MMP-1 (TIMP-1) in vascular endothelial cells \[[@CR69], [@CR70]\].

Our study also revealed that HSE is an important differential diagnosis of lobar hemorrhage as 32% had a hemorrhage detected on initial neuroimaging. This emphasizes the need for sufficient medical history, as the patients almost exclusively presented with an encephalitic syndrome. Moreover, it should be noted that hemorrhage in the temporal lobe needs to be investigated with appropriate vascular imaging in order to rule out vascular malformations or other causes of atypical hemorrhage.

It has been recognized since the early 1970s that HSE can occasionally present with a cerebral infarction \[[@CR71]\]. An epidemiological study of HSE from the USA reported ischemic complications occurring twice as frequently (5.6%) as hemorrhage. Both cases with hemorrhage as the presenting imaging feature and brain infarction later during the course were related to HSV-2 with evidence of vasculitis. HSV-1 was the causative agent in the only patient with classical temporal lobe encephalitis who developed infarction. There was only one case of brain stem infarction caused by HSV-2, which is another encephalitic predilection site of HSV-2. Imaging findings of vasculitis include stenosis, vessel wall thickening, and enhancement \[[@CR72]\]. If knowledge from VZV vasculopathy can be translated, the lack of CSF pleocytosis or of angiographic abnormalities should not preclude the diagnosis of vasculopathy. Indeed, in VZV vasculopathy, up to 33% of cases may have normal CSF and 30% may have negative vascular imaging \[[@CR73]\]. Thus, confirmation of vasculitis on neuroimaging should not be the decisive factor for considering adjunctive steroid treatment. Little is known about the exact mechanisms of action leading to HSV vasculitis. In case of VZV disease, cerebral vessels demonstrate fibrinoid necrosis, intimal proliferation, loss of elastic lamina, and a lymphocytic or monocytic inflammatory infiltrate with surrounding multinucleated giant cells \[[@CR74]\]. Additional mechanism of action may include an immune-mediated process leading to vasospasm and thrombosis and hypercoagulable state in combination with endothelial dysfunction resulting from activation of inflammatory and pro-coagulant cascades \[[@CR9]\].

We acknowledge several limitations to our study. A publishing bias for more severe and atypical cases must be anticipated. This might also explain higher rates of hemorrhage than infarction. In addition, imaging techniques and time points of investigations differed within our cohort. Furthermore, vasculitic change in small vessels may not be picked up by non-invasive angiography. Future studies should ideally employ MRI with standardized vascular imaging and a PCR methodology which differentiates between HSV-1 and HSV-2. There was only a single case of venous sinus thrombosis, for which significant conclusions cannot be drawn.

Conclusion {#Sec10}
==========

We expand the understanding for HSV-related cerebrovascular disease and report distinct pathogenesis, cause, and outcome for cerebral hemorrhage and infarction. Further studies should focus on strategies to prevent intracerebral hemorrhage including avoidance of impaired coagulation and management of life-threatening consequences. In addition, HSV-related infarction is a rare but potentially treatable cause of stroke caused by large vessel vasculitis and usually does not clinically present as a stroke. Steroid treatment can be considered even in the absence of confirmation of vasculitis on neuroimaging.
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